Recently Added Drugs
1. Amyvid patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7687052 | AVID RADIOPHARMS INC | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques |
Apr, 2027
(1 year, 6 months from now) | |
| US8506929 | AVID RADIOPHARMS INC | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques |
Apr, 2027
(1 year, 6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 06, 2017 |
Drugs and Companies using FLORBETAPIR F-18 ingredient
NCE-1 date: 06 April, 2016
Market Authorisation Date: 06 April, 2012
Treatment: Pet to estimate amyloid beta neuritic plaque density in adults with cognitive impairment: -evaluation of alzheimer’s disease and other causes of cognitive decline -selection of patients who are indica...
Dosage: SOLUTION
More Information on Dosage
AMYVID family patents
2. Anzupgo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8609647 | LEO PHARMA AS | NA |
Sep, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2030 |
Drugs and Companies using DELGOCITINIB ingredient
NCE-1 date: 23 July, 2029
Market Authorisation Date: 23 July, 2025
Treatment: Method of inhibiting janus kinase 2 or janus kinase 3 to treat moderate to severe chronic hand eczema (che) in adults who have had an inadequate response to, or for whom topical corticosteroids are no...
Dosage: CREAM
More Information on Dosage
ANZUPGO family patents
3. Arikayce Kit patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12377114 | INSMED INC | NA |
May, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-214) | Sep 28, 2025 |
| Generating Antibiotic Incentives Now(GAIN) | Sep 28, 2030 |
Drugs and Companies using AMIKACIN SULFATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination drug regimen
Dosage: SUSPENSION, LIPOSOMAL
More Information on Dosage
ARIKAYCE KIT family patents
4. Aristada patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12311027 | ALKERMES INC | NA |
Sep, 2033
(7 years from now) | |
| US11969469 | ALKERMES INC | NA |
Oct, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 05, 2020 |
Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient
NCE-1 date: 06 October, 2019
Market Authorisation Date: 05 October, 2015
Treatment: Treatment of schizophrenia
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
ARISTADA family patents
5. Atmeksi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12390439 | ROSEMONT PHARMS | NA |
Oct, 2044
(19 years from now) | |
Drugs and Companies using METHOCARBAMOL ingredient
Market Authorisation Date: 30 July, 2025
Treatment: Atmeksi is indicated as an adjunct to rest, physical therapy, and other measures for the relief and discomfort associated with acute, painful musculoskeletal conditions
Dosage: SUSPENSION
More Information on Dosage
ATMEKSI family patents
6. Atorvaliq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12370136 | CMP DEV LLC | NA |
Jun, 2037
(11 years from now) | |
Drugs and Companies using ATORVASTATIN CALCIUM ingredient
Market Authorisation Date: 01 February, 2023
Treatment: NA
Dosage: SUSPENSION
More Information on Dosage
ATORVALIQ family patents
7. Auvelity patent expiration
Can you believe AUVELITY received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12390428 | AXSOME | NA |
Dec, 2041
(16 years from now) | |
| US12357697 | AXSOME | NA |
Jan, 2043
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 18, 2025 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient
Market Authorisation Date: 18 August, 2022
Treatment: Dextromethorphan and bupropion in combination to treat major depressive disorder
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of AUVELITY before it's drug patent expiration?
More Information on Dosage
AUVELITY family patents
8. Belrapzo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12350257 | EAGLE PHARMS | NA |
Jan, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| ODE*(ODE*) | Dec 07, 2022 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 May, 2018
Treatment: For the treatment of patients with indolent b-cell non-hodgkin lymphoma
Dosage: SOLUTION
How can I launch a generic of BELRAPZO before it's drug patent expiration?
More Information on Dosage
BELRAPZO family patents
9. Bendeka patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12350257 | EAGLE PHARMS | NA |
Jan, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-179) | Dec 07, 2022 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 December, 2015
Treatment: For the treatment of patients with indolent b-cell non-hodgkin lymphoma
Dosage: SOLUTION
How can I launch a generic of BENDEKA before it's drug patent expiration?
More Information on Dosage
BENDEKA family patents
10. Brinsupri patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10287258 | INSMED INC | NA |
Jan, 2035
(9 years from now) | |
| US10669245 | INSMED INC | NA |
Jan, 2035
(9 years from now) | |
| US11655222 | INSMED INC | NA |
Jan, 2035
(9 years from now) | |
| US11655223 | INSMED INC | NA |
Jan, 2035
(9 years from now) | |
| US11814359 | INSMED INC | NA |
Jan, 2035
(9 years from now) | |
| US12054465 | INSMED INC | NA |
Jan, 2035
(9 years from now) | |
| US9522894 | INSMED INC | NA |
Mar, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11655221 | INSMED INC | NA |
Jan, 2035
(9 years from now) | |
| US11655224 | INSMED INC | NA |
Jan, 2035
(9 years from now) | |
| US11673871 | INSMED INC | NA |
Jan, 2035
(9 years from now) | |
| US11773069 | INSMED INC | NA |
Jan, 2035
(9 years from now) | |
| US9815805 | INSMED INC | NA |
Jan, 2035
(9 years from now) | |
| US12201638 | INSMED INC | NA |
Mar, 2039
(13 years from now) | |
| US12059424 | INSMED INC | NA |
Feb, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 12, 2030 |
Drugs and Companies using BRENSOCATIB ingredient
NCE-1 date: 12 August, 2029
Market Authorisation Date: 12 August, 2025
Treatment: Treatment of non-cystic fibrosis bronchiectasis in patients 12 years of age and older
Dosage: TABLET
More Information on Dosage
BRINSUPRI family patents
11. Brixadi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12318379 | BRAEBURN | NA |
Jul, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 23, 2026 |
Drugs and Companies using BUPRENORPHINE ingredient
Market Authorisation Date: 23 May, 2023
Treatment: A method of treating moderate to severe opioid use disorder by administering buprenorphine once weekly
Dosage: SOLUTION, EXTENDED RELEASE
More Information on Dosage
BRIXADI family patents
12. Bynfezia Pen patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12350475 | SUN PHARM | NA |
Dec, 2041
(16 years from now) | |
Drugs and Companies using OCTREOTIDE ACETATE ingredient
Market Authorisation Date: 27 September, 2024
Treatment: Method of treating severe diarrhea and flushing episodes associated with metastatic carcinoid tumors
Dosage: SOLUTION
More Information on Dosage
BYNFEZIA PEN family patents
13. Calcium Gluconate In Sodium Chloride patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10130646 | FRESENIUS KABI USA | Calcium gluconate solutions in flexible containers |
Jul, 2037
(11 years from now) | |
Drugs and Companies using CALCIUM GLUCONATE ingredient
Market Authorisation Date: 15 June, 2017
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
CALCIUM GLUCONATE IN SODIUM CHLORIDE family patents
14. Crexont patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12370163 | IMPAX | NA |
Dec, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 07, 2027 |
Drugs and Companies using CARBIDOPA; LEVODOPA ingredient
Market Authorisation Date: 07 August, 2024
Treatment: Treatment of parkinsonism that may follow manganese intoxication
Dosage: CAPSULE, EXTENDED RELEASE
More Information on Dosage
CREXONT family patents
15. Cyclophosphamide patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12329767 | DR REDDYS | NA |
Feb, 2036
(10 years from now) | |
Drugs and Companies using CYCLOPHOSPHAMIDE ingredient
Market Authorisation Date: 30 July, 2020
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of CYCLOPHOSPHAMIDE before it's drug patent expiration?
More Information on Dosage
CYCLOPHOSPHAMIDE family patents
16. Doptelet Sprinkle patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7638536 | AKARX INC | 2-Acylaminothiazole derivative or salt thereof |
Jul, 2027
(1 year, 9 months from now) | |
Drugs and Companies using AVATROMBOPAG MALEATE ingredient
Market Authorisation Date: 24 July, 2025
Treatment: NA
Dosage: GRANULE
More Information on Dosage
DOPTELET SPRINKLE family patents
17. Ekterly patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10364238 | KALVISTA | NA |
Nov, 2035
(10 years from now) | |
| US11001578 | KALVISTA | NA |
Nov, 2035
(10 years from now) | |
| US11084809 | KALVISTA | NA |
Nov, 2035
(10 years from now) | |
| US11230537 | KALVISTA | NA |
Dec, 2037
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10611758 | KALVISTA | NA |
Nov, 2035
(10 years from now) | |
| US11198691 | KALVISTA | NA |
Nov, 2035
(10 years from now) | |
| US11739068 | KALVISTA | NA |
Jun, 2037
(11 years from now) | |
| US11234939 | KALVISTA | NA |
Jan, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 03, 2030 |
Drugs and Companies using SEBETRALSTAT ingredient
NCE-1 date: 03 July, 2029
Market Authorisation Date: 03 July, 2025
Treatment: Treatment of acute attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older
Dosage: TABLET
More Information on Dosage
EKTERLY family patents
18. Envarsus Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12403095 | VELOXIS PHARMS INC | NA |
May, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jul 10, 2022 |
| Orphan Drug Exclusivity(ODE-94) | Jul 10, 2022 |
Drugs and Companies using TACROLIMUS ingredient
Market Authorisation Date: 10 July, 2015
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of ENVARSUS XR before it's drug patent expiration?
More Information on Dosage
ENVARSUS XR family patents
19. Evrysdi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12350273 | GENENTECH INC | NA |
Oct, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | May 27, 2025 |
| New Chemical Entity Exclusivity(NCE) | Aug 07, 2025 |
| M(M-270) | Oct 03, 2026 |
| Orphan Drug Exclusivity(ODE-334) | Aug 07, 2027 |
| Orphan Drug Exclusivity(ODE-400) | May 27, 2029 |
Drugs and Companies using RISDIPLAM ingredient
NCE-1 date: 07 August, 2024
Market Authorisation Date: 07 August, 2020
Treatment: Treatment of spinal muscular atrophy
Dosage: FOR SOLUTION; TABLET
More Information on Dosage
EVRYSDI family patents
20. Exparel patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12370142 | PACIRA PHARMS INC | NA |
Jul, 2044
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 28, 2014 |
| New Indication(I-771) | Apr 06, 2021 |
| New Patient Population(NPP) | Mar 22, 2024 |
| New Indication(I-929) | Nov 09, 2026 |
Drugs and Companies using BUPIVACAINE ingredient
Market Authorisation Date: 28 October, 2011
Treatment: Method of treating pain, for example, via infiltration for local analgesia; Or via interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, or adductor canal block for reg...
Dosage: INJECTABLE, LIPOSOMAL
How can I launch a generic of EXPAREL before it's drug patent expiration?
More Information on Dosage
EXPAREL family patents
21. Fabhalta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12384758 | NOVARTIS | NA |
May, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-949) | Aug 07, 2027 |
| New Indication(I-963) | Mar 20, 2028 |
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2028 |
| Orphan Drug Exclusivity(ODE-456) | Dec 05, 2030 |
Drugs and Companies using IPTACOPAN HYDROCHLORIDE ingredient
NCE-1 date: 06 December, 2027
Market Authorisation Date: 05 December, 2023
Treatment: Treatment of complement 3 glomerulopathy (c3g)
Dosage: CAPSULE
More Information on Dosage
FABHALTA family patents
22. Furoscix patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12370168 | SCPHARMACEUTICALS | NA |
Apr, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 07, 2025 |
Drugs and Companies using FUROSEMIDE ingredient
Market Authorisation Date: 07 October, 2022
Treatment: Use of a liquid formulation comprising furosemide to treat congestion due to fluid overload (edema) in adults with nyha class ii/iii chronic heart failure
Dosage: SOLUTION
More Information on Dosage
FUROSCIX family patents
23. Gemtesa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12357636 | SUMITOMO PHARMA AM | NA |
May, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2025 |
| New Indication(I-955) | Dec 18, 2027 |
Drugs and Companies using VIBEGRON ingredient
NCE-1 date: 23 December, 2024
Market Authorisation Date: 23 December, 2020
Treatment: Treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacological therapy for benign prostatic hyperplasia (bph)
Dosage: TABLET
More Information on Dosage
GEMTESA family patents
24. Gimoti patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12377064 | EVOKE PHARMA INC | NA |
Nov, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 19, 2023 |
Drugs and Companies using METOCLOPRAMIDE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 June, 2020
Treatment: Nasal administration of metoclopramide for treatment of diabetic gastroparesis
Dosage: SPRAY, METERED
How can I launch a generic of GIMOTI before it's drug patent expiration?
More Information on Dosage
GIMOTI family patents
25. Glyxambi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US12115179 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Aug, 2030
(4 years from now) | |
|
US11833166 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Oct, 2034
(8 years from now) | |
| US12364700 | BOEHRINGER INGELHEIM | NA |
Jun, 2037
(11 years from now) | |
|
US12364700 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Dec, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jan 30, 2018 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient
NCE-1 date: 01 August, 2018
Market Authorisation Date: 30 January, 2015
Treatment: Treatment of type 2 diabetes in a patient having estimated glomerular filtration rate levels down to 30 ml/minute/1.73 m2, albuminuria and previous macrovascular disease by administering linagliptin i...
Dosage: TABLET
How can I launch a generic of GLYXAMBI before it's drug patent expiration?
More Information on Dosage
GLYXAMBI family patents
26. Gomekli patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12357597 | SPRINGWORKS | NA |
Feb, 2041
(15 years from now) | |
| US12383517 | SPRINGWORKS | NA |
Mar, 2044
(18 years from now) | |
| US12390430 | SPRINGWORKS | NA |
Oct, 2044
(19 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 11, 2030 |
| Orphan Drug Exclusivity(ODE-488) | Feb 11, 2032 |
Drugs and Companies using MIRDAMETINIB ingredient
NCE-1 date: 11 February, 2029
Market Authorisation Date: 11 February, 2025
Treatment: Treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (nf1) who have symptomatic plexiform neurofibromas (pn) not amenable to complete resection
Dosage: CAPSULE
More Information on Dosage
GOMEKLI family patents
27. Hernexeos patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12171739 | BOEHRINGER INGELHEIM | NA |
Nov, 2026
(1 year, 1 month from now) | |
| US11608343 | BOEHRINGER INGELHEIM | NA |
Jul, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 08, 2030 |
Drugs and Companies using ZONGERTINIB ingredient
NCE-1 date: 08 August, 2029
Market Authorisation Date: 08 August, 2025
Treatment: Use of zongertinib for treating non-small cell lung cancer (nsclc)
Dosage: TABLET
More Information on Dosage
HERNEXEOS family patents
28. Igalmi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12364683 | BIOXCEL | NA |
Jan, 2043
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 05, 2025 |
Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 April, 2022
Treatment: Acute treatment of agitation in patients with severe hepatic impairment
Dosage: FILM
More Information on Dosage
IGALMI family patents
29. Imbruvica patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12364698 | PHARMACYCLICS LLC | NA |
Apr, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-680) | Feb 12, 2017 |
| New Indication(I-689) | Jul 28, 2017 |
| New Indication(I-702) | Jan 29, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 13, 2018 |
| New Indication(I-729) | Mar 04, 2019 |
| New Dosing Schedule(D-165) | May 06, 2019 |
| New Indication(I-736) | May 06, 2019 |
| New Indication(I-737) | May 06, 2019 |
| New Indication(I-741) | Jan 18, 2020 |
| New Indication(I-753) | Aug 02, 2020 |
| Orphan Drug Exclusivity(ODE-55) | Nov 13, 2020 |
| Orphan Drug Exclusivity(ODE-60) | Feb 12, 2021 |
| Orphan Drug Exclusivity(ODE-72) | Jul 28, 2021 |
| New Dosing Schedule(D-176) | Aug 24, 2021 |
| M(M-236) | Jan 25, 2022 |
| Orphan Drug Exclusivity(ODE-86) | Jan 29, 2022 |
| Orphan Drug Exclusivity(ODE-109) | Mar 04, 2023 |
| Orphan Drug Exclusivity(ODE-117) | May 06, 2023 |
| Orphan Drug Exclusivity(ODE-128) | Jan 18, 2024 |
| Orphan Drug Exclusivity(ODE) | Aug 02, 2024 |
| ODE*(ODE*) | Aug 02, 2024 |
| Orphan Drug Exclusivity(ODE-152) | Aug 02, 2024 |
| M(M-14) | Aug 24, 2025 |
| New Product(NP) | Aug 24, 2025 |
| New Patient Population(NPP) | Aug 24, 2025 |
| Pediatric Exclusivity(PED) | Feb 24, 2026 |
| Orphan Drug Exclusivity(ODE-405) | Aug 24, 2029 |
Drugs and Companies using IBRUTINIB ingredient
Market Authorisation Date: 24 August, 2022
Treatment: NA
Dosage: SUSPENSION
How can I launch a generic of IMBRUVICA before it's drug patent expiration?
More Information on Dosage
IMBRUVICA family patents
30. Jardiance patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US12115179 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Aug, 2030
(4 years from now) | |
|
US11813275 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Oct, 2034
(8 years from now) | |
|
US11833166 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Oct, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-159) | Jun 26, 2018 |
| M(M-160) | Jun 26, 2018 |
| M(M-161) | Jun 26, 2018 |
| M(M-174) | Mar 18, 2019 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| New Indication(I-869) | Aug 18, 2024 |
| M(M-82) | Feb 24, 2025 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
| New Patient Population(NPP) | Jun 20, 2026 |
| New Indication(I-922) | Sep 21, 2026 |
Drugs and Companies using EMPAGLIFLOZIN ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 01 August, 2014
Treatment: NA
Dosage: TABLET
How can I launch a generic of JARDIANCE before it's drug patent expiration?
More Information on Dosage
JARDIANCE family patents
31. Jentadueto patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12364700 | BOEHRINGER INGELHEIM | NA |
Jun, 2037
(11 years from now) | |
|
US12364700 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Dec, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jan 30, 2015 |
| New Chemical Entity Exclusivity(NCE) | May 02, 2016 |
| M(M-146) | Jul 30, 2017 |
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 30 January, 2012
Treatment: Treatment of type 2 diabetes in a patient having estimated glomerular filtration rate levels down to 30 ml/minute/1.73 m2, albuminuria and previous macrovascular disease by administering linagliptin i...
Dosage: TABLET
How can I launch a generic of JENTADUETO before it's drug patent expiration?
More Information on Dosage
JENTADUETO family patents
32. Jentadueto Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12364700 | BOEHRINGER INGELHEIM | NA |
Jun, 2037
(11 years from now) | |
|
US12364700 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Dec, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 May, 2016
Treatment: Treatment of type 2 diabetes in a patient having estimated glomerular filtration rate levels down to 30 ml/minute/1.73 m2, albuminuria and previous macrovascular disease by administering linagliptin i...
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of JENTADUETO XR before it's drug patent expiration?
More Information on Dosage
JENTADUETO XR family patents
33. Kerendia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8436180 | BAYER HLTHCARE | Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof |
Apr, 2029
(3 years from now) | |
| USRE49826 | BAYER HLTHCARE | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient |
Jul, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-279) | Sep 01, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jul 09, 2026 |
| New Indication(I-970) | Jul 11, 2028 |
| New Strength(NS) | Jul 11, 2028 |
Drugs and Companies using FINERENONE ingredient
NCE-1 date: 09 July, 2025
Market Authorisation Date: 09 July, 2021
Treatment: NA
Dosage: TABLET
More Information on Dosage
KERENDIA family patents
34. Khindivi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11904046 | ETON | NA |
Feb, 2043
(17 years from now) | |
| US12133914 | ETON | NA |
Feb, 2043
(17 years from now) | |
Drugs and Companies using HYDROCORTISONE ingredient
Market Authorisation Date: 28 May, 2025
Treatment: Treatment of adrenal insufficiency with an oral liquid formulation of hydrocortisone; Treatment of primary or secondary adrenocortical insufficiency with an oral liquid formulation of hydrocortisone
Dosage: SOLUTION
More Information on Dosage
KHINDIVI family patents
35. Koselugo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12364684 | ASTRAZENECA | NA |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 10, 2025 |
| Orphan Drug Exclusivity(ODE-288) | Apr 10, 2027 |
Drugs and Companies using SELUMETINIB SULFATE ingredient
NCE-1 date: 10 April, 2024
Market Authorisation Date: 10 April, 2020
Treatment: Treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (nf1) who have symptomatic, inoperable plexiform neurofibromas (pn)
Dosage: CAPSULE
More Information on Dosage
KOSELUGO family patents
36. Krazati patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12336995 | BRISTOL | NA |
Feb, 2041
(15 years from now) | |
| US12383503 | BRISTOL | NA |
Aug, 2043
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 12, 2027 |
| Orphan Drug Exclusivity(ODE-352) | Dec 12, 2029 |
Drugs and Companies using ADAGRASIB ingredient
NCE-1 date: 12 December, 2026
Market Authorisation Date: 12 December, 2022
Treatment: Treatment, in combination with cetuximab, of adult patients with kras g12c-muted locally advanced or metastatic colorectal cancer, per fda approved test, where prior treatment with fluoropyrimidine-, ...
Dosage: TABLET
More Information on Dosage
KRAZATI family patents
37. Kyzatrex patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12357643 | MARIUS | NA |
Mar, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 27, 2025 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 27 July, 2022
Treatment: Method of treating testosterone deficiency
Dosage: CAPSULE
More Information on Dosage
KYZATREX family patents
38. Leqselvi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12364699 | SUN PHARM INDS INC | NA |
Oct, 2044
(19 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 25, 2029 |
Drugs and Companies using DEURUXOLITINIB PHOSPHATE ingredient
NCE-1 date: 25 July, 2028
Market Authorisation Date: 25 July, 2024
Treatment: Treatment of adult patients with alopecia areata
Dosage: TABLET
More Information on Dosage
LEQSELVI family patents
39. Livmarli patent expiration
Can you believe LIVMARLI received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11260053 | MIRUM | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
May, 2031
(5 years from now) | |
| US12350267 | MIRUM | NA |
Oct, 2032
(7 years from now) | |
| US10512657 | MIRUM | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
Oct, 2032
(7 years from now) | |
| US11229661 | MIRUM | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
Oct, 2032
(7 years from now) | |
| US11376251 | MIRUM | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
Oct, 2032
(7 years from now) | |
| US11229647 | MIRUM | Methods for treating cholestasis |
Feb, 2040
(14 years from now) | |
| US11497745 | MIRUM | Methods for treating cholestasis |
Feb, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Mar 13, 2026 |
| New Chemical Entity Exclusivity(NCE) | Sep 29, 2026 |
| New Indication(I-938) | Mar 13, 2027 |
| ODE*(ODE*) | Sep 29, 2028 |
| Orphan Drug Exclusivity(ODE-379) | Sep 29, 2028 |
| Orphan Drug Exclusivity(ODE-429) | Mar 13, 2030 |
| Orphan Drug Exclusivity(ODE-471) | Mar 13, 2031 |
| Orphan Drug Exclusivity(ODE-490) | Jul 24, 2031 |
Drugs and Companies using MARALIXIBAT CHLORIDE ingredient
NCE-1 date: 29 September, 2025
Market Authorisation Date: 10 April, 2025
Treatment: Treatment of cholestatic pruritus in patients 3 months of age and older with alagille syndrome (algs) who weigh 25 kilograms and above; Treatment of cholestatic pruritus in patients 12 months of age a...
Dosage: TABLET; SOLUTION
More Information on Dosage
LIVMARLI family patents
40. Lodoco patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12364675 | AGEPHA PHARMA FZ | NA |
Nov, 2033
(8 years from now) | |
Drugs and Companies using COLCHICINE ingredient
Market Authorisation Date: 16 June, 2023
Treatment: A method for treating and/or reducing the risk of a cardiovascular event
Dosage: TABLET
More Information on Dosage
LODOCO family patents
41. Lumakras patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12398133 | AMGEN INC | NA |
May, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2026 |
| New Indication(I-962) | Jan 16, 2028 |
| ODE*(ODE*) | May 28, 2028 |
| Orphan Drug Exclusivity(ODE-352) | May 28, 2028 |
| Orphan Drug Exclusivity(ODE-507) | Jan 16, 2032 |
Drugs and Companies using SOTORASIB ingredient
NCE-1 date: 28 May, 2025
Market Authorisation Date: 28 May, 2021
Treatment: Treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda-approved test, who have received at least one prior system...
Dosage: TABLET
More Information on Dosage
LUMAKRAS family patents
42. Lybalvi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12390474 | ALKERMES INC | NA |
Nov, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2026 |
Drugs and Companies using OLANZAPINE; SAMIDORPHAN L-MALATE ingredient
NCE-1 date: 28 May, 2025
Market Authorisation Date: 28 May, 2021
Treatment: NA
Dosage: TABLET
More Information on Dosage
LYBALVI family patents
43. Modeyso patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9629842 | CHIMERIX | NA |
Apr, 2032
(6 years from now) | |
| USRE46290 | CHIMERIX | NA |
Apr, 2032
(6 years from now) | |
| US9265765 | CHIMERIX | NA |
Jul, 2034
(8 years from now) | |
| US11976068 | CHIMERIX | NA |
Mar, 2036
(10 years from now) | |
| US10172862 | CHIMERIX | NA |
Jan, 2037
(11 years from now) | |
| US10369154 | CHIMERIX | NA |
Jan, 2037
(11 years from now) | |
| US12102639 | CHIMERIX | NA |
Jan, 2037
(11 years from now) | |
Drugs and Companies using DORDAVIPRONE HYDROCHLORIDE ingredient
Market Authorisation Date: 06 August, 2025
Treatment: Method of treating adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an h3 k27m mutation with progressive disease following prior therapy
Dosage: CAPSULE
More Information on Dosage
MODEYSO family patents
44. Mounjaro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12343382 | ELI LILLY AND CO | NA |
Jul, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 13, 2027 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 July, 2023
Treatment: Treatment of type 2 diabetes by administering a once weekly escalation dose of 2.5 mg, 7.5 mg, or 12.5 mg of tirzepatide for at least 2 weeks and a once-weekly maintenance dose of 5 mg, 10 mg, or 15 m...
Dosage: SOLUTION
More Information on Dosage
MOUNJARO family patents
45. Mounjaro (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12343382 | ELI LILLY AND CO | NA |
Jul, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 13, 2027 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 July, 2023
Treatment: Treatment of type 2 diabetes by administering a once weekly escalation dose of 2.5 mg, 7.5 mg, or 12.5 mg of tirzepatide for at least 2 weeks and a once-weekly maintenance dose of 5 mg, 10 mg, or 15 m...
Dosage: SOLUTION
More Information on Dosage
MOUNJARO (AUTOINJECTOR) family patents
46. Neuraceq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9308284 | LIFE MOLECULAR | NA |
Jul, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 21, 2019 |
Drugs and Companies using FLORBETABEN F-18 ingredient
NCE-1 date: 21 March, 2018
Market Authorisation Date: 19 March, 2014
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
NEURACEQ family patents
47. Nexletol patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12398087 | ESPERION THERAPS INC | NA |
Jun, 2040
(14 years from now) | |
| US12404227 | ESPERION THERAPS INC | NA |
Jun, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 21, 2025 |
| New Indication(I-943) | Mar 22, 2027 |
| New Indication(I-944) | Mar 22, 2027 |
Drugs and Companies using BEMPEDOIC ACID ingredient
NCE-1 date: 22 February, 2024
Market Authorisation Date: 21 February, 2020
Treatment: A method of treating primary hyperlipidemia using bempedoic acid
Dosage: TABLET
More Information on Dosage
NEXLETOL family patents
48. Nexlizet patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12398087 | ESPERION THERAPS INC | NA |
Jun, 2040
(14 years from now) | |
| US12404227 | ESPERION THERAPS INC | NA |
Jun, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 26, 2023 |
| New Chemical Entity Exclusivity(NCE) | Feb 21, 2025 |
| New Indication(I-943) | Mar 22, 2027 |
| New Indication(I-945) | Mar 22, 2027 |
Drugs and Companies using BEMPEDOIC ACID; EZETIMIBE ingredient
NCE-1 date: 22 February, 2024
Market Authorisation Date: 26 February, 2020
Treatment: A method of treating primary hyperlipidemia using bempedoic acid
Dosage: TABLET
More Information on Dosage
NEXLIZET family patents
49. Omlonti patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12295946 | OCUVEX THERAP | NA |
Jan, 2035
(9 years from now) | |
| US12290511 | OCUVEX THERAP | NA |
Dec, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 22, 2027 |
Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient
NCE-1 date: 22 September, 2026
Market Authorisation Date: 22 September, 2022
Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients
Dosage: SOLUTION
More Information on Dosage
OMLONTI family patents
50. Onivyde patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12364691 | IPSEN | NA |
Jun, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 22, 2018 |
| Orphan Drug Exclusivity(ODE) | Oct 22, 2022 |
| Orphan Drug Exclusivity(ODE-99) | Oct 22, 2022 |
| New Indication(I-932) | Feb 13, 2027 |
| Orphan Drug Exclusivity(ODE-463) | Feb 13, 2031 |
Drugs and Companies using IRINOTECAN HYDROCHLORIDE ingredient
Market Authorisation Date: 22 October, 2015
Treatment: Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin
Dosage: INJECTABLE, LIPOSOMAL
More Information on Dosage
ONIVYDE family patents
51. Opsumit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7094781 (Pediatric) | ACTELION | NA |
Jun, 2026
(7 months from now) | |
|
US10946015 (Pediatric) | ACTELION | NA |
Mar, 2027
(1 year, 5 months from now) | |
|
US9265762 (Pediatric) | ACTELION | NA |
Nov, 2027
(2 years from now) | |
|
US8367685 (Pediatric) | ACTELION | NA |
Apr, 2029
(3 years from now) | |
|
US8268847 (Pediatric) | ACTELION | NA |
Oct, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 18, 2018 |
| Orphan Drug Exclusivity(ODE) | Oct 18, 2020 |
| Orphan Drug Exclusivity(ODE-54) | Oct 18, 2020 |
| M(M-187) | Feb 28, 2028 |
| Pediatric Exclusivity(PED) | Aug 28, 2028 |
Drugs and Companies using MACITENTAN ingredient
NCE-1 date: 29 August, 2027
Market Authorisation Date: 18 October, 2013
Treatment: NA
Dosage: TABLET
How can I launch a generic of OPSUMIT before it's drug patent expiration?
More Information on Dosage
OPSUMIT family patents
52. Opsynvi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7094781 (Pediatric) | ACTELION | NA |
Jun, 2026
(7 months from now) | |
|
US10946015 (Pediatric) | ACTELION | NA |
Mar, 2027
(1 year, 5 months from now) | |
|
US8268847 (Pediatric) | ACTELION | NA |
Oct, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 22, 2027 |
| Orphan Drug Exclusivity(ODE-475) | Mar 22, 2031 |
| Pediatric Exclusivity(PED) | Sep 22, 2031 |
Drugs and Companies using MACITENTAN; TADALAFIL ingredient
Market Authorisation Date: 22 March, 2024
Treatment: NA
Dosage: TABLET
More Information on Dosage
OPSYNVI family patents
53. Orladeyo patent expiration
Can you believe ORLADEYO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12344585 | BIOCRYST | NA |
Nov, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 03, 2025 |
| Orphan Drug Exclusivity(ODE-333) | Dec 03, 2027 |
Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient
NCE-1 date: 03 December, 2024
Market Authorisation Date: 03 December, 2020
Treatment: Prophylaxis to prevent attacks of hereditary angioedema (hae) in adult and pediatric patients 12 years of age and older
Dosage: CAPSULE
More Information on Dosage
ORLADEYO family patents
54. Otrexup patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12357642 | ASSERTIO SPECLTY | NA |
Mar, 2030
(4 years from now) | |
Drugs and Companies using METHOTREXATE ingredient
Market Authorisation Date: 07 November, 2014
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
OTREXUP family patents
55. Pemfexy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12115164 | EAGLE PHARMS | NA |
Feb, 2036
(10 years from now) | |
Drugs and Companies using PEMETREXED ingredient
Market Authorisation Date: 08 February, 2020
Treatment: For use in the treatment of patients with malignant pleural mesothelioma and/or locally advanced or metastatic non-squamous non-small cell lung cancer (nsclc)
Dosage: SOLUTION
More Information on Dosage
PEMFEXY family patents
56. Posluma patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12390540 | BLUE EARTH | NA |
Aug, 2038
(12 years from now) | |
| US12357711 | BLUE EARTH | NA |
Nov, 2038
(13 years from now) | |
| US12377176 | BLUE EARTH | NA |
Nov, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 25, 2028 |
Drugs and Companies using FLOTUFOLASTAT F-18 GALLIUM ingredient
NCE-1 date: 26 May, 2027
Market Authorisation Date: 25 May, 2023
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
POSLUMA family patents
57. Prevduo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12383491 | AZURITY | NA |
Oct, 2038
(13 years from now) | |
Drugs and Companies using GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE ingredient
Market Authorisation Date: 23 February, 2023
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
PREVDUO family patents
58. Qulipta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12383545 | ABBVIE | NA |
Jun, 2039
(13 years from now) | |
| US12090148 | ABBVIE | Treatment of migraine |
Jul, 2041
(15 years from now) | |
| US12350259 | ABBVIE | NA |
Feb, 2043
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-909) | Apr 17, 2026 |
| New Chemical Entity Exclusivity(NCE) | Sep 28, 2026 |
Drugs and Companies using ATOGEPANT ingredient
NCE-1 date: 28 September, 2025
Market Authorisation Date: 28 September, 2021
Treatment: Preventive treatment of migraine in adults; Preventive treatment of migraine in adults undergoing concurrent treatment with a strong cyp3a4 inhibitor
Dosage: TABLET
More Information on Dosage
QULIPTA family patents
59. Rapiblyk patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10722516 | AOP ORPHAN | NA |
Apr, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 22, 2029 |
Drugs and Companies using LANDIOLOL HYDROCHLORIDE ingredient
NCE-1 date: 22 November, 2028
Market Authorisation Date: 22 November, 2024
Treatment: A method of reducing the heart rate of a subject suffering from supraventricular tachycardia, wherein landiolol is administered parenterally at a constant dose of more than 20 mcg/kg/min for 2-20 hour...
Dosage: POWDER
More Information on Dosage
RAPIBLYK family patents
60. Recorlev patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12377096 | STRONGBRIDGE | NA |
Mar, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCE*(NCE*) | Dec 30, 2026 |
| Orphan Drug Exclusivity(ODE-385) | Dec 30, 2028 |
Drugs and Companies using LEVOKETOCONAZOLE ingredient
Market Authorisation Date: 30 December, 2021
Treatment: During levoketoconazole dosage titration for the treatment of cushing's syndrome in patients who concomitantly use a mate1 substrate, monitoring the subject for a dose limiting event and adjusting the...
Dosage: TABLET
More Information on Dosage
RECORLEV family patents
61. Rezdiffra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12377104 | MADRIGAL | NA |
Feb, 2045
(19 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 14, 2029 |
Drugs and Companies using RESMETIROM ingredient
NCE-1 date: 14 March, 2028
Market Authorisation Date: 14 March, 2024
Treatment: Treatment of adults with noncirrhotic nonalcoholic steatohepatitis (nash) with moderate to advanced liver fibrosis (consistent with stages f2 to f3 fibrosis)
Dosage: TABLET
More Information on Dosage
REZDIFFRA family patents
62. Rhofade patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12350255 | MAYNE PHARMA | NA |
Jun, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 18, 2020 |
Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 January, 2017
Treatment: Once daily topical treatment of persistent facial erythema associated with rosacea in female adults
Dosage: CREAM
How can I launch a generic of RHOFADE before it's drug patent expiration?
More Information on Dosage
RHOFADE family patents
63. Rinvoq Lq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12365689 | ABBVIE | NA |
Oct, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 16, 2024 |
| New Product(NP) | Apr 26, 2027 |
| Orphan Drug Exclusivity(ODE-481) | Apr 26, 2031 |
Drugs and Companies using UPADACITINIB ingredient
NCE-1 date: 17 August, 2023
Market Authorisation Date: 26 April, 2024
Treatment: Treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more tnf blockers
Dosage: SOLUTION
More Information on Dosage
RINVOQ LQ family patents
64. Rybelsus patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12396953 | NOVO | NA |
Feb, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 20, 2022 |
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| M(M-252) | Jan 16, 2023 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 09 December, 2024
Treatment: Method of treating type 2 diabetes mellitus
Dosage: TABLET
More Information on Dosage
RYBELSUS family patents
65. Ryzumvi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12350366 | FAMYGEN LIFE SCI | NA |
Jan, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 25, 2026 |
Drugs and Companies using PHENTOLAMINE MESYLATE ingredient
Market Authorisation Date: 25 September, 2023
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
RYZUMVI family patents
66. Sephience patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11072614 | PTC THERAP | NA |
Apr, 2038
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11752154 | PTC THERAP | NA |
Sep, 2038
(12 years from now) | |
| US12213982 | PTC THERAP | NA |
Sep, 2038
(12 years from now) | |
| US12257252 | PTC THERAP | NA |
Mar, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 28, 2030 |
Drugs and Companies using SEPIAPTERIN ingredient
NCE-1 date: 28 July, 2029
Market Authorisation Date: 28 July, 2025
Treatment: Treatment of hyperphenylalaninemia (hpa) in adult and pediatric patients with sepiapterin-responsive phenylketonuria (pku) by administering sepiapterin; Method of treating hyperphenylalaninemia (hpa) ...
Dosage: POWDER
More Information on Dosage
SEPHIENCE family patents
67. Sofdra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12357609 | BOTANIX SB | NA |
May, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 20, 2029 |
Drugs and Companies using SOFPIRONIUM BROMIDE ingredient
NCE-1 date: 20 June, 2028
Market Authorisation Date: 18 June, 2024
Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
Dosage: GEL, METERED
More Information on Dosage
SOFDRA family patents
68. Sotalol Hydrochloride patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12390431 | ALTATHERA PHARMS LLC | NA |
Aug, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jul 02, 2016 |
Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient
Market Authorisation Date: 02 July, 2009
Treatment: Dosing regimen for intravenous sotalol for administration in a facility that can provide continuous electrocardiographic monitoring and cardiac resuscitation.
Dosage: SOLUTION
More Information on Dosage
SOTALOL HYDROCHLORIDE family patents
69. Sunosi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12384743 | AXSOME MALTA | NA |
Nov, 2038
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12390419 | AXSOME MALTA | NA |
Sep, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2024 |
| Orphan Drug Exclusivity(ODE-254) | Jun 17, 2026 |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
NCE-1 date: 18 June, 2023
Market Authorisation Date: 17 June, 2019
Treatment: To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa)
Dosage: TABLET
How can I launch a generic of SUNOSI before it's drug patent expiration?
More Information on Dosage
SUNOSI family patents
70. Symbravo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12370196 | AXSOME | NA |
Dec, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 30, 2028 |
Drugs and Companies using MELOXICAM; RIZATRIPTAN BENZOATE ingredient
Market Authorisation Date: 30 January, 2025
Treatment: Acute treatment of migraine
Dosage: TABLET
More Information on Dosage
SYMBRAVO family patents
71. Symproic patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12350377 | BDSI | NA |
May, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 23, 2022 |
Drugs and Companies using NALDEMEDINE TOSYLATE ingredient
NCE-1 date: 23 March, 2021
Market Authorisation Date: 23 March, 2017
Treatment: NA
Dosage: TABLET
More Information on Dosage
SYMPROIC family patents
72. Synjardy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US12115179 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Aug, 2030
(4 years from now) | |
|
US11813275 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Oct, 2034
(8 years from now) | |
|
US11833166 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Oct, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 26, 2018 |
| M(M-174) | Mar 18, 2019 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| New Patient Population(NPP) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 26 August, 2015
Treatment: NA
Dosage: TABLET
How can I launch a generic of SYNJARDY before it's drug patent expiration?
More Information on Dosage
SYNJARDY family patents
73. Synjardy Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US12115179 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Aug, 2030
(4 years from now) | |
|
US11813275 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Oct, 2034
(8 years from now) | |
|
US11833166 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Oct, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| M(M-296) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 09 December, 2016
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of SYNJARDY XR before it's drug patent expiration?
More Information on Dosage
SYNJARDY XR family patents
74. Tradjenta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12364700 | BOEHRINGER INGELHEIM | NA |
Jun, 2037
(11 years from now) | |
|
US12364700 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Dec, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-118) | Aug 13, 2015 |
| M(M-121) | Aug 13, 2015 |
| New Chemical Entity Exclusivity(NCE) | May 02, 2016 |
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 02 May, 2011
Treatment: Treatment of type 2 diabetes in a patient having estimated glomerular filtration rate levels down to 30 ml/minute/1.73 m2, albuminuria and previous macrovascular disease by administering linagliptin i...
Dosage: TABLET
How can I launch a generic of TRADJENTA before it's drug patent expiration?
More Information on Dosage
TRADJENTA family patents
75. Trijardy Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US12115179 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Aug, 2030
(4 years from now) | |
|
US11833166 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Oct, 2034
(8 years from now) | |
| US12364700 | BOEHRINGER INGELHEIM | NA |
Jun, 2037
(11 years from now) | |
|
US12364700 (Pediatric) | BOEHRINGER INGELHEIM | NA |
Dec, 2037
(12 years from now) | |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 January, 2020
Treatment: Treatment of type 2 diabetes in a patient having estimated glomerular filtration rate levels down to 30 ml/minute/1.73 m2, albuminuria and previous macrovascular disease by administering linagliptin i...
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of TRIJARDY XR before it's drug patent expiration?
More Information on Dosage
TRIJARDY XR family patents
76. Trikafta (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE50453 | VERTEX PHARMS INC | NA |
May, 2027
(1 year, 6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12350262 | VERTEX PHARMS INC | NA |
Jul, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 08, 2024 |
| New Chemical Entity Exclusivity(NCE) | Oct 21, 2024 |
| New Product(NP) | Apr 26, 2026 |
| Orphan Drug Exclusivity(ODE-275) | Oct 21, 2026 |
| M(M-313) | Dec 20, 2027 |
| ODE*(ODE*) | Dec 21, 2027 |
| Orphan Drug Exclusivity(ODE-323) | Dec 21, 2027 |
| Orphan Drug Exclusivity(ODE-357) | Jun 08, 2028 |
| Orphan Drug Exclusivity(ODE-433) | Apr 26, 2030 |
| Orphan Drug Exclusivity(ODE-512) | Dec 20, 2031 |
Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient
NCE-1 date: 22 October, 2023
Market Authorisation Date: 08 June, 2021
Treatment: Treatment of cf in patients aged 2 to <6 years old who have in the cftr gene at least one f508del mutation or a responsive mutation based on clinical and/or in vitro data by administering daily elx/te...
Dosage: TABLET; GRANULES
More Information on Dosage
TRIKAFTA (COPACKAGED) family patents
77. Tryptyr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12336971 | ALCON LABS INC | NA |
Dec, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2030 |
Drugs and Companies using ACOLTREMON ingredient
NCE-1 date: 28 May, 2029
Market Authorisation Date: 28 May, 2025
Treatment: Treatment of the signs and symptoms of dry eye disease (ded)
Dosage: SOLUTION/DROPS
More Information on Dosage
TRYPTYR family patents
78. Twyneo patent expiration
Can you believe TWYNEO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12357602 | MAYNE PHARMA | NA |
Jul, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jul 26, 2024 |
Drugs and Companies using BENZOYL PEROXIDE; TRETINOIN ingredient
Market Authorisation Date: 26 July, 2021
Treatment: Topical treatment of acne
Dosage: CREAM
More Information on Dosage
TWYNEO family patents
79. Tybost patent expiration
TYBOST's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8148374 | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8148374 (Pediatric) | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Mar, 2030
(4 years from now) | |
| US10039718 | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Oct, 2032
(7 years from now) | |
|
US10039718 (Pediatric) | GILEAD SCIENCES INC | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
Apr, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
| New Product(NP) | Sep 24, 2017 |
| New Patient Population(NPP) | Aug 22, 2022 |
| Orphan Drug Exclusivity(ODE-260) | Aug 22, 2026 |
Drugs and Companies using COBICISTAT ingredient
NCE-1 date: 27 August, 2016
Market Authorisation Date: 20 June, 2025
Treatment: Treatment of hiv infection using a composition containing a pharmacokinetic enhancer that inhibits cytochrome p450 monooxygenase
Dosage: TABLET
How can I launch a generic of TYBOST before it's drug patent expiration?
More Information on Dosage
TYBOST family patents
80. Ubrelvy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12329750 | ABBVIE | NA |
Dec, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2024 |
Drugs and Companies using UBROGEPANT ingredient
NCE-1 date: 24 December, 2023
Market Authorisation Date: 23 December, 2019
Treatment: Acute treatment of migraine with or without aura in a patient undergoing treatment with a bcrp and/or p-gp only inhibitor
Dosage: TABLET
More Information on Dosage
UBRELVY family patents
81. Uzedy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12383493 | TEVA | NA |
Sep, 2040
(14 years from now) | |
| US12329851 | TEVA | NA |
Mar, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 28, 2026 |
Drugs and Companies using RISPERIDONE ingredient
Market Authorisation Date: 28 April, 2023
Treatment: Treatment of schizophrenia; A method of switching a patient from daily oral risperidone therapy to a long-acting injectable risperidone formulation
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
UZEDY family patents
82. Vanrafia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12370174 | NOVARTIS | NA |
Dec, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 02, 2030 |
Drugs and Companies using ATRASENTAN HYDROCHLORIDE ingredient
NCE-1 date: 02 April, 2029
Market Authorisation Date: 02 April, 2025
Treatment: Treatment of primary immunoglobulin a nephropathy (igan)
Dosage: TABLET
More Information on Dosage
VANRAFIA family patents
83. Velsipity patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12377071 | PFIZER | NA |
Jan, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 12, 2028 |
Drugs and Companies using ETRASIMOD ARGININE ingredient
NCE-1 date: 13 October, 2027
Market Authorisation Date: 12 October, 2023
Treatment: A method for treating ulcerative colitis by administering estrasimod l-arginine in an amount equivalent to about 2.0 mg of estrasimod
Dosage: TABLET
More Information on Dosage
VELSIPITY family patents
84. Vizz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10052313 | LENZ THERAP | NA |
Mar, 2034
(8 years from now) | |
| US11179328 | LENZ THERAP | NA |
Mar, 2034
(8 years from now) | |
| US9844537 | LENZ THERAP | NA |
Mar, 2034
(8 years from now) | |
| US12128036 | LENZ THERAP | NA |
Oct, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2030 |
Drugs and Companies using ACECLIDINE HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2029
Market Authorisation Date: 31 July, 2025
Treatment: Treatment of presbyopia
Dosage: SOLUTION/DROPS
More Information on Dosage
VIZZ family patents
85. Vostally patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12343338 | ROSEMONT PHARMS | NA |
Aug, 2039
(13 years from now) | |
Drugs and Companies using RAMIPRIL ingredient
Market Authorisation Date: 23 July, 2025
Treatment: Vostally is indicated for the treatment of hypertension, to lower blood pressure
Dosage: SOLUTION
More Information on Dosage
VOSTALLY family patents
86. Wegovy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11478533 | NOVO | NA |
May, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| New Product(NP) | Jun 04, 2024 |
| New Patient Population(NPP) | Dec 23, 2025 |
| New Dosing Schedule(D-190) | Jul 21, 2026 |
| New Indication(I-935) | Mar 08, 2027 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 04 June, 2021
Treatment: Treatment of adults with noncirrhotic nonalcoholic steatohepatitis (nash) with moderate to advanced liver fibrosis (consistent with stages f2 to f3 fibrosis)
Dosage: SOLUTION
How can I launch a generic of WEGOVY before it's drug patent expiration?
More Information on Dosage
WEGOVY family patents
87. Welireg patent expiration
Can you believe WELIREG received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12358870 | MERCK SHARP DOHME | NA |
Jun, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2026 |
| New Indication(I-931) | Dec 14, 2026 |
| New Indication(I-968) | May 14, 2028 |
| Orphan Drug Exclusivity(ODE-364) | Aug 13, 2028 |
Drugs and Companies using BELZUTIFAN ingredient
NCE-1 date: 13 August, 2025
Market Authorisation Date: 13 August, 2021
Treatment: NA
Dosage: TABLET
More Information on Dosage
WELIREG family patents
88. Winlevi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12337002 | SUN PHARM | NA |
Jul, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 26, 2025 |
Drugs and Companies using CLASCOTERONE ingredient
NCE-1 date: 26 August, 2024
Market Authorisation Date: 26 August, 2020
Treatment: Method of treating acne vulgaris with topically applied cortexolone 17alpha-propionate
Dosage: CREAM
More Information on Dosage
WINLEVI family patents
89. Xdemvy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12364685 | TARSUS | NA |
Dec, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 24, 2028 |
Drugs and Companies using LOTILANER ingredient
NCE-1 date: 25 July, 2027
Market Authorisation Date: 24 July, 2023
Treatment: NA
Dosage: SOLUTION/DROPS
More Information on Dosage
XDEMVY family patents
90. Yeztugo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9951043 | GILEAD SCIENCES INC | Therapeutic compounds |
Feb, 2034
(8 years from now) | |
| US10071985 | GILEAD SCIENCES INC | Therapeutic compounds |
Aug, 2037
(11 years from now) | |
| US11267799 | GILEAD SCIENCES INC | Solid forms of an HIV capsid inhibitor |
Aug, 2038
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11807625 | GILEAD SCIENCES INC | NA |
Nov, 2040
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 22, 2027 |
| New Product(NP) | Jun 18, 2028 |
Drugs and Companies using LENACAPAVIR SODIUM ingredient
NCE-1 date: 22 December, 2026
Market Authorisation Date: 18 June, 2025
Treatment: For pre-exposure prophylaxis to reduce the risk of sexually acquired hiv-1 in adults and adolescents weighing at least 35 kg who are at risk for hiv-1 acquisition
Dosage: SOLUTION; TABLET
More Information on Dosage
YEZTUGO family patents
91. Yorvipath patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12403182 | ASCENDIS PHARMA BONE | NA |
Nov, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 09, 2027 |
| New Chemical Entity Exclusivity(NCE) | Aug 09, 2029 |
| Orphan Drug Exclusivity(ODE-492) | Aug 09, 2031 |
Drugs and Companies using PALOPEGTERIPARATIDE ingredient
NCE-1 date: 09 August, 2028
Market Authorisation Date: 09 August, 2024
Treatment: Treatment of hypoparathyroidism in adults
Dosage: SOLUTION
More Information on Dosage
YORVIPATH family patents
92. Yutrepia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12390475 | LIQUIDIA TECH | NA |
May, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 23, 2028 |
Drugs and Companies using TREPROSTINIL SODIUM ingredient
Market Authorisation Date: 23 May, 2025
Treatment: NA
Dosage: POWDER
More Information on Dosage
YUTREPIA family patents
93. Zegfrovy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11007198 | DIZAL JIANGSU | NA |
Jan, 2039
(13 years from now) | |
| US11504375 | DIZAL JIANGSU | NA |
Jan, 2039
(13 years from now) | |
| US11896597 | DIZAL JIANGSU | NA |
Jan, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 02, 2030 |
Drugs and Companies using SUNVOZERTINIB ingredient
NCE-1 date: 02 July, 2029
Market Authorisation Date: 02 July, 2025
Treatment: Treatment of patients with non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 20 exon insertion mutations whose disease has progressed on or after platinum-based chem...
Dosage: TABLET
More Information on Dosage
ZEGFROVY family patents
94. Zepbound patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12343382 | ELI LILLY AND CO | NA |
Jul, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 13, 2027 |
| M(M-82) | Oct 18, 2027 |
| New Indication(I-958) | Dec 20, 2027 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 March, 2024
Treatment: Method of improving weight management by administering a once weekly escalation dose of 2.5 mg, 7.5 mg, or 12.5 mg of tirzepatide for at least 2 weeks and a once-weekly maintenance dose of 5 mg, 10 mg...
Dosage: SOLUTION
More Information on Dosage
ZEPBOUND family patents
95. Zepbound (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12343382 | ELI LILLY AND CO | NA |
Jul, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 08, 2026 |
| New Chemical Entity Exclusivity(NCE) | May 13, 2027 |
| M(M-82) | Oct 18, 2027 |
| New Indication(I-958) | Dec 20, 2027 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 March, 2024
Treatment: Method of treating obesity by administering a once weekly escalation dose of 2.5 mg, 7.5 mg, or 12.5 mg of tirzepatide for at least 2 weeks and a once-weekly maintenance dose of 5 mg, 10 mg, or 15 mg ...
Dosage: SOLUTION
More Information on Dosage
ZEPBOUND (AUTOINJECTOR) family patents
96. Zoryve patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12336983 | ARCUTIS | NA |
Jun, 2037
(11 years from now) | |
| US12329751 | ARCUTIS | NA |
Dec, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 15, 2026 |
| New Patient Population(NPP) | Oct 05, 2026 |
| New Strength(NS) | Jul 09, 2027 |
| New Indication(I-969) | May 22, 2028 |
Drugs and Companies using ROFLUMILAST ingredient
Market Authorisation Date: 09 July, 2024
Treatment: Topical treatment of seborrheic dermatitis in patients 9 years of age and older
Dosage: FOAM; CREAM
More Information on Dosage
ZORYVE family patents
97. Zusduri patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10039832 | UROGEN PHARMA | NA |
Jan, 2031
(5 years from now) | |
| US9040074 | UROGEN PHARMA | Material and method for treating internal cavities |
Jan, 2031
(5 years from now) | |
| US9950069 | UROGEN PHARMA | Material and method for treating internal cavities |
Jan, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 12, 2028 |
Drugs and Companies using MITOMYCIN ingredient
Market Authorisation Date: 12 June, 2025
Treatment: Treatment of adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer
Dosage: POWDER
More Information on Dosage
ZUSDURI family patents
98. Zykadia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12357630 | NOVARTIS | NA |
Dec, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 29, 2019 |
| M(M-199) | May 26, 2020 |
| Orphan Drug Exclusivity(ODE-66) | Apr 29, 2021 |
| Orphan Drug Exclusivity(ODE) | May 26, 2024 |
| ODE*(ODE*) | May 26, 2024 |
| Orphan Drug Exclusivity(ODE-145) | May 26, 2024 |
Drugs and Companies using CERITINIB ingredient
NCE-1 date: 29 April, 2018
Market Authorisation Date: 18 March, 2019
Treatment: Treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors are anaplastic lymphoma kinase (alk)-positive as detected by an fda-approved test
Dosage: TABLET
More Information on Dosage
ZYKADIA family patents